Free Trial

Eliem Therapeutics (ELYM) Competitors

→ You need to know these two things about AI stocks ASAP… (From InvestorPlace) (Ad)
Free ELYM Stock Alerts
$8.95
-0.37 (-3.97%)
(As of 05/9/2024 ET)
Compare
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

ELYM vs. TELO, GTHX, VERU, LFCR, DSGN, ZVRA, ALIM, TRVI, ATOS, and GBIO

Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Telomir Pharmaceuticals (TELO), G1 Therapeutics (GTHX), Veru (VERU), Lifecore Biomedical (LFCR), Design Therapeutics (DSGN), Zevra Therapeutics (ZVRA), Alimera Sciences (ALIM), Trevi Therapeutics (TRVI), Atossa Therapeutics (ATOS), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.

Eliem Therapeutics vs.

Telomir Pharmaceuticals (NASDAQ:TELO) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Eliem Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A N/A N/A
Eliem Therapeutics N/A -31.45%-30.43%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$13.07MN/AN/A
Eliem TherapeuticsN/AN/A-$35.12M-$1.47-6.09

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Telomir Pharmaceuticals Neutral
Eliem Therapeutics Neutral

Eliem Therapeutics received 9 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.

CompanyUnderperformOutperform
Telomir PharmaceuticalsN/AN/A
Eliem TherapeuticsOutperform Votes
9
56.25%
Underperform Votes
7
43.75%

Summary

Telomir Pharmaceuticals and Eliem Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELYM vs. The Competition

Export to Excel
MetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$248.13M$7.01B$5.16B$7.78B
Dividend YieldN/A2.76%2.84%3.96%
P/E Ratio-6.0925.09188.8319.04
Price / SalesN/A280.412,307.2685.27
Price / CashN/A20.2533.5428.62
Price / Book2.295.725.314.62
Net Income-$35.12M$140.01M$105.28M$217.57M
7 Day Performance-11.87%-0.35%-0.26%0.58%
1 Month Performance235.21%-3.46%-2.28%-0.70%
1 Year Performance140.59%-3.31%3.22%9.12%

Eliem Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TELO
Telomir Pharmaceuticals
0 of 5 stars		$6.62
-8.9%		N/AN/A$196.02MN/A0.001
GTHX
G1 Therapeutics
4.1658 of 5 stars		$3.77
+1.3%		$9.33
+147.6%		+68.8%$197.21M$82.51M-3.97100
VERU
Veru
1.1154 of 5 stars		$1.35
+8.0%		$3.33
+146.9%		+0.0%$197.61M$16.30M-1.80189
LFCR
Lifecore Biomedical
1.3544 of 5 stars		$6.42
-0.6%		$9.50
+48.0%		+49.3%$194.65M$103.27M-1.92459
DSGN
Design Therapeutics
2.1845 of 5 stars		$3.52
-5.4%		$5.50
+56.3%		-36.8%$198.85MN/A-2.9358Upcoming Earnings
Analyst Upgrade
ZVRA
Zevra Therapeutics
1.0062 of 5 stars		$4.58
+0.7%		$19.50
+325.8%		+13.5%$198.91M$27.46M-3.5532Analyst Revision
News Coverage
ALIM
Alimera Sciences
2.5341 of 5 stars		$3.68
+0.3%		$7.50
+103.8%		+94.3%$192.65M$80.75M-1.70154
TRVI
Trevi Therapeutics
2.7454 of 5 stars		$2.93
-0.3%		$8.50
+190.1%		-3.3%$202.05MN/A-10.1025Analyst Forecast
ATOS
Atossa Therapeutics
1.138 of 5 stars		$1.51
-1.3%		$4.50
+198.0%		+134.7%$189.20MN/A-6.2912
GBIO
Generation Bio
1.4061 of 5 stars		$2.83
-0.7%		$8.00
+182.7%		-32.4%$188.17M$5.90M-1.44174News Coverage

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ELYM) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners
The Crypto 9-5 Escape Plan
Crypto 101 Media
Gold Set to EXPLODE!
Gold Safe Exchange
He Is Giving Away Bitcoin
Crypto Swap Profits
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
Banyan Hill Publishing
Charles Payne Demystifies Options
Unstoppable Prosperity
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The 2024 Gold Rush: Unleashing Market Potential
Priority Gold
[URGENT] DO NOT Touch These AI Stocks!
Weiss Ratings